Liver and Kidney Dysfunction: What Stem Cell Evidence Can Tell You
Human studies exist, but the evidence isn’t one-size-fits-all. Liver data mainly concern selected cirrhosis populations; a recent kidney study focused on CKD stages G3b–G4 and excluded dialysis. If both organs are affected, two separate studies can’t be smushed into one expected outcome.
We provide medical-information and care-navigation support: organizing your records, matching your case to published human evidence, preparing questions, and helping you understand what’s known before you make a costly decision.
Where the evidence stands
Use the numbers without turning them into promises
The FDA approved Ryoncil in December 2024 for pediatric steroid-refractory acute graft-versus-host disease. That approval does not extend to liver or kidney dysfunction.[1]
Cell research should not be used to postpone liver-transplant assessment when transplantation is medically indicated.[2]
Hemodialysis, peritoneal dialysis, kidney transplantation and conservative management for selected patients remain established pathways.[3]
Cell source, dose, route, disease subtype, stage and expected endpoint must be compared with a human study that resembles the individual case.
Controlled studies in adults with decompensated cirrhosis; evidence current to 4 October 2024.
Individual trials ranged from 27 to 219 participants.
41/308 in stem-cell groups versus 78/269 in controls over 3–75 months. Cochrane rated the evidence very low certainty.[5]
108 patients received three IV umbilical-cord MSC infusions at 4-week intervals; 111 were controls; follow-up reached 75 months.[4]
A study percentage describes a selected population, product and follow-up period. It is not a personal success rate.Cochrane 2025 and disease-specific human studies cited above.
Want a clearer answer from your own records?
Send the key results you already have. We’ll help identify what’s missing and which published evidence actually applies.
Does the research fit your case?
Check the study population before the headline result
The 219-patient trial excluded renal failure. It does not establish the same result for simultaneous liver-kidney dysfunction, compensated cirrhosis, metabolic fatty liver disease, acute liver failure, liver cancer or other causes.[4]
The 2026 study enrolled adults aged 20–80 with eGFR 15–44. Ongoing dialysis, hepatitis and hepatic insufficiency were among the exclusions.[10]
Group-based trajectory modeling classified 88.24% of 34 treated patients as showing an improvement or stabilization trend over 48 weeks. The study was small and all dose groups received active cells.[6]
KDIGO uses both eGFR and urine albumin-to-creatinine ratio to classify CKD risk. eGFR 45 or higher, eGFR below 15, or ongoing dialysis falls outside the recent G3b–G4 study population.[7][10]
What you can actually measure
Improvement needs a definition
Compare repeated results with your own pre-treatment trend. One better lab value isn’t durable organ recovery.
Track bilirubin, albumin and INR rather than relying on a single symptom report.
MELD, Child-Pugh status and decompensation events are more informative than “detox” or “regeneration” language.
Track serial eGFR rather than creatinine alone. Compare the slope before and after any intervention over months, not days.
Urine albumin or protein trends matter because CKD risk is assessed with both filtration and albuminuria.[7]
Admissions, infection, ascites, bleeding, dialysis start, transplant status and other major outcomes should not be hidden behind better laboratory numbers.
Follow-up must be long enough to mean something. The liver trial tracked liver-function measures through 48 weeks and survival through 75 months; the 2026 CKD phase I/II study followed patients for 48 weeks. A single early result cannot be compared directly with those study outcomes.[4][6]
What proven treatment already says
Do not miss treatment that already has strong evidence
The key question is not only whether cell research exists. It is whether proven treatment for the underlying cause has already been optimized.
Liver
NIDDK notes that direct-acting antiviral medicines can cure more than 95% of people with chronic hepatitis C in 8 to 12 weeks. Clearing the virus is not the same as reversing established cirrhosis.[2]
Antiviral treatment can slow or stop further viral liver damage; this should not be replaced by a general regenerative claim.[2]
Liver transplantation remains the established replacement treatment when failure is present and transplant is appropriate.[2]
Kidney
KDIGO classifies CKD using cause, GFR category and albuminuria category. That risk profile matters before any experimental discussion.[7]
Current CKD care is built around evidence-based treatment of the cause and kidney/cardiovascular risk factors, not cell therapy alone.[7]
Hemodialysis, peritoneal dialysis and kidney transplantation are established kidney-replacement options; conservative management is also used for selected patients.[3]
What the evidence can’t tell you yet
Know what is not established — and when not to wait
What research does not prove
Urgent deterioration comes first
AASLD notes that acute kidney injury occurs in about 20% of hospitalized patients with cirrhosis. Rapid simultaneous liver-kidney deterioration needs medical assessment first.[9]
Regulatory status is indication-specific
Before you commit
Verify the protocol and the quote separately
A responsible proposal should be specific enough for you and your doctor to understand what is being offered and what is not included.
Details that can be checked
Cell source, autologous or allogeneic status, processing method and product name when one exists.
Cells per dose, number of administrations, interval and route. “Stem cell therapy” alone is not a usable protocol description.
Ask what release testing is used for identity, viability, sterility and product-specific quality criteria.
Ask whether it is an approved product, a clinical trial, or care provided under another legal framework, and for which indication.
Know which laboratory or clinical endpoints will be used and when they will be repeated.
Ask who handles fever, allergic reactions, infection, worsening organ function or other complications.
Cost clarity
There isn’t a guideline-defined standard price for a stem-cell intervention aimed at liver or kidney dysfunction. A higher price isn’t proof of a better result.
Record review, laboratory tests, imaging and any additional specialist assessment.
Source or collection, processing, quality controls, dose and number of administrations.
Follow-up testing, review, translation or coordination, and care not included in the original quotation.
Compare quotations only after the exact product, dose, testing, monitoring and follow-up are itemized.
Where we come in
A structured review before you commit
You’ll get a structured case-information package: organized records, a match to relevant human evidence, focused questions, and practical communication support before you commit time, travel or money.
Organize your records
We structure laboratory trends, imaging, diagnosis history and current treatment into a concise case summary.
Match the evidence
We compare the proposed cell type and protocol with human studies that resemble your disease rather than relying on broad regenerative claims.
Prepare focused questions
We help you ask about product identity, evidence quality, realistic endpoints, risks, follow-up and what happens if the plan does not work as hoped.
Support communication
We assist with information exchange and translation so you can understand the proposal before making travel or payment decisions.
Not sure which part of your report changes the answer?
Start with the latest tests and the diagnosis history you already have. We’ll help spot the missing pieces before you spend time comparing options.
What to send for a useful first review
Send records that can change the answer
Preferably 3–6 months: bilirubin, albumin and INR for liver; creatinine/eGFR and urine ACR or protein for kidney.
Ultrasound, CT, MRI, elastography or kidney imaging linked to the diagnosis.
Cause, stage, major complications, admissions, procedures and previous treatment.
Medication list, dialysis details and transplant evaluation status when relevant.
Active infection, cancer history, bleeding risk, diabetes control, immune suppression, hepatitis status and cardiovascular disease.
Tell us what you most need clarified: evidence, cost, preparation, timing or how to compare options.
Related reading
Explore connected topics before you decide
Use these resources to understand regenerative medicine, screening information and other condition-focused research without treating one condition as evidence for another.
What patients ask us
Answers worth having before any decision
A useful answer is specific, measurable and tied to your exact disease—not a general claim about regeneration.
Can stem cells cure liver or kidney dysfunction?
Can cell therapy replace transplant or dialysis?
Does the kidney study apply if I am on dialysis or also have serious liver disease?
Is there a proven stem-cell survival rate?
How quickly should improvement appear?
What is the strongest evidence to ask for?
What should an itemized quotation include?
What should I send for a first information review?
Next step
Start with the information you already have
Send your latest results and a short history. We’ll help organize the case, sort out which evidence matters and make the next conversation clearer—before you commit time, travel or money.
These pages are for medical information and care-navigation support. They don’t diagnose disease, prescribe treatment, guarantee eligibility or promise a clinical outcome. Decisions about urgent care, medication, dialysis, transplantation or any cell-based intervention should be made with qualified medical professionals who know your case.